January 24, 2014

The FDA has banned the import of drugs from a factory run by India’s Ranbaxy Laboratories due to quality control violations. FDA inspectors found Ranbaxy workers violating U.S. manufacturing standards by retesting drug ingredients that had failed quality testing, in an effort to return positive results. Ranbaxy, with an annual revenue of $2+ billion is India’s largest drug manufacturer - and it has fallen short of U.S. quality standards before. The company will have to hire an independent inspector to ensure that the plant meets U.S. quality standards before the ban can be lifted. Said Carol Bennett, FDA compliance director, "The FDA is committed to ensuring that the drugs American consumers receive — no matter where they are produced — meet quality standards and are safe and effective.”